Spinal cord injury - Case Study- Stem cell therapy- Giostar
a brief introduction to Giostar and its Stem cell therapy Dr.Divyang Patel (MD) a spine surgeon at Giostar- INDIA, briefs about a case of cervical spine injury, which is also examined by a...
By: Devang Parmar
The rest is here:
Spinal cord injury - Case Study- Stem cell therapy- Giostar - Video
GIOSTAR- STEM CELL THERAPY DR ANAND SHRIVASTAVA
Global Institute of Stem cell Therapy and Research - GIOSTAR Introduction to Stem Cell Therapy, and Dr.Anand Shrivastava - Chairman Co-founder of GIOSTAR.
By: Devang Parmar
See the original post here:
GIOSTAR- STEM CELL THERAPY & DR ANAND SHRIVASTAVA - Video
Contact Information
Available for logged-in reporters only
Newswise Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes.
The trial will assess the safety and efficacy of a new investigational drug called VC-01, which was recently approved for testing by the U.S. Food and Drug Administration. The 2-year trial will involve four to six testing sites, the first being at UC San Diego, and will recruit approximately 40 study participants.
The goal, first and foremost, of this unprecedented human trial is to evaluate the safety, tolerability and efficacy of various doses of VC-01 among patients with type 1 diabetes mellitus, said principal investigator Robert R. Henry, MD, professor of medicine in the Division of Endocrinology and Metabolism at UC San Diego and chief of the Section of Endocrinology, Metabolism & Diabetes at the Veterans Affairs San Diego Healthcare System. We will be implanting specially encapsulated stem cell-derived cells under the skin of patients where its believed they will mature into pancreatic beta cells able to produce a continuous supply of needed insulin. Previous tests in animals showed promising results. We now need to determine that this approach is safe in people.
Development and testing of VC-01 is funded, in part, by the California Institute for Regenerative Medicine, the states stem cell agency, the UC San Diego Sanford Stem Cell Clinical Center and JDRF, the leading research and advocacy organization funding type 1 diabetes research.
Type 1 diabetes mellitus is a life-threatening chronic condition in which the pancreas produces little or no insulin, a hormone needed to allow glucose to enter cells to produce energy. It is typically diagnosed during childhood or adolescence, though it can also begin in adults. Though far less common than Type 2 diabetes, which occurs when the body becomes resistant to insulin, Type 1 may affect up to 3 million Americans, according to the JDRF. Among Americans age 20 and younger, prevalence rose 23 percent between 2000 and 2009 and continues to rise. Currently, there is no cure. Standard treatment involves daily injections of insulin and rigorous management of diet and lifestyle.
Phase I/II clinical trials are designed to assess basic safety and efficacy of therapies never before tested in humans, uncovering unforeseen risks or complications. Unpredictable outcomes are possible. Such testing is essential to ensure that the new therapy is developed responsibly with appropriate management of risks that all medical treatments may present.
This is not yet a cure for diabetes, said Henry. The hope, nonetheless, is that this approach will ultimately transform the way individuals with Type 1 diabetes manage their disease by providing an alternative source of insulin-producing cells, potentially freeing them from daily insulin injections or external pumps.
This clinical trial at UC San Diego Health System was launched and supported by the UC San Diego Sanford Stem Cell Clinical Center. The Center was recently created to advance leading-edge stem cell medicine and science, protect and counsel patients, and accelerate innovative stem cell research into patient diagnostics and therapy.
Read more here:
Clinical Trial to Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes
Melbourne, Florida (PRWEB) September 11, 2014
Central Florida board-certified veterinary surgeon, Jeffrey S. Christiansen is proud to announce his partnerships with several Brevard County animal hospitals to bring regenerative veterinary medicine to pets. Dr. Christiansen has been working in the area since January 2006, credentialed to do stem cell therapy on small animals since 2008, and is happy to now offer his expertise through five different locations.
Over the years Dr. Christiansen has used stem cell therapy with Vet-Stem, Inc. on cruciate ligament and meniscus injuries, as well as osteoarthritis of the hips and other joints. Once Dr. Christiansen has identified a patient as a good stem cell therapy candidate, the pet undergoes a simple surgery to collect fat that is sent overnight to Vet-Stems lab in California. The day after the collection the fat is processed so stem cells can be extracted and put into concentrated, injectable doses. These doses are shipped back overnight to Dr. Christiansen and he is able to place them in the affected areas of the patient to encourage healing and regeneration.
Even if a pet is not an immediate candidate for stem cell therapy, but is undergoing an orthopedic or other type of surgery with Dr. Christiansen, he offers the ability to collect a small sample of fat for future stem cell use with Vet-Stem. Vet-Stem has the ability to cryo-bank stem cells and grow them in the future to provide doses when needed. This service is called StemInsure for dogs, and provides the insurance of a pet having a lifetime of stem cell therapy available from a single sample collection.
Stem cell therapy can be an alternative for pets that are unable to take anti-inflammatories or have digestive issues, as well as pets that are looking at long-term pain management. Because the stem cells come directly from the patient risk is low, and the procedure is natural.
As part of Superior Veterinary Surgical (and less-invasive) Solutions, Dr. Christiansen will be offering stem cell therapy at the following clinics beginning in September: Island Animal Hospital in Merritt Island, Brevard Animal Emergency Hospital in Malabar, Aloha Pet and Bird Hospital in Indian Harbour, Maybeck Animal Hospital in West Melbourne, and the Animal Emergency and Referral Center in Fort Pierce. He is bringing nearly 20 years of veterinary medicine experience with him, and takes pride in specializing in soft tissue, orthopedic, and spinal surgery.
About Dr. Christiansen and Superior Veterinary Surgical Solutions Jeffrey S. Christiansen, DVM, DACVS graduated from the University of Tennessee College of Veterinary Medicine in 1996. He completed his surgical residency in 2001, following an internship, and in 2002 he became a Diplomate of the American College of Veterinary Surgeons. Dr. Christiansen has been practicing in Brevard County since the beginning of 2006 and runs Superior Veterinary Surgical Solutions. In addition to stem cell therapy, some special areas of interest to Dr. Christiansen include artificial urethral sphincter (for incontinence), juvenile pubic symphysiodesis (for prevention of arthritis secondary to hip dysplasia), prophylactic gastropexy (for prevention of gastric dilatation-volvulus, commonly referred to as bloat), subcutaneous ureteral bypass (for obstructions between the kidney and bladder in cats), ureteral stenting (for obstruction between the kidney and bladder in dogs), and urethral stenting (for urethral obstruction), tibial tuberosity advancement (for tears of the cranial cruciate ligament; ACL in people) and tracheal stenting (for tracheal collapse).
About Vet-Stem, Inc. Since its formation in 2002, Vet-Stem, Inc. has endeavored to improve the lives of animals through regenerative medicine. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem pioneered the use of regenerative stem cells for horses, dogs, cats, and some exotics. In 2004 the first horse was treated with Vet-Stem Regenerative Cell Therapy for a tendon injury that would normally have been career ending. Ten years later Vet-Stem celebrated its 10,000th animal treated, and the success of establishing stem cell therapy as a regenerative medicine for certain inflammatory, degenerative, and arthritic diseases. As animal advocates, veterinarians, veterinary technicians, and cell biologists, the team at Vet-Stem tasks themselves with the responsibility of discovering, refining, and bringing to market innovative medical therapies that utilize the bodys own healing and regenerative cells. For more information about Vet-Stem and Regenerative Veterinary Medicine visit http://www.vet-stem.com or call 858-748-2004.
Read the rest here:
Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond
San Antonio, TX (PRWEB) September 11, 2014
The Stem Cell Institute, located in Panama City, Panama, will present an informational seminar about umbilical cord stem cell therapy on Saturday, September 20, 2014 in San Antonio, Texas at the La Cantera Hill Country Resort from 1:00 pm to 4:00 pm.
Stem Cell Institute Speakers include:
Neil Riordan PhD Umbilical Cord Stem Cell Clinical Trials for MS and Autism: Rationale and Clinical Protocols
Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.
Jorge Paz-Rodriguez MD Umbilical Cord Stem Cell Therapy for Arthritis, Inflammation and Sports Injuries
Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.
Special Guest Speaker:
Janet Vaughan, DDS, MS, Professional Dancer- Successful Stem Cell Therapy in Panama: A Patients Perspective
Dr. Vaughan is Board Certified in Orthodontics (Diplomate of the American Board of Orthodontics) and she is a Fellow in the International College of Dentistry.
Freeport, Grand Bahama (PRWEB) September 08, 2014
Adult stem cell therapy for heart disease has emerged as a new treatment alternative for those living with a poor quality of life as a result of severe coronary artery disease. Okyanos is slated to begin delivering this innovative new treatment in the next several weeks, and is now screening qualified heart disease candidates. The procedure will be performed in their newly constructed state-of-the-art Phillips catheterization lab, as announced last month.
Just 50 miles from US shore, Okyanos cardiac cell therapy is available to qualified patients with advanced stages of coronary artery disease (CAD) and congestive heart failure (CHF). The screening process consists of a thorough review of your medical history by the Okyanos Chief Medical Officer and Cardiologist, Dr. Howard Walpole, as well as consultation done in conjunction with your cardiologist. You must be able to travel as the protocol is delivered in Freeport on Grand Bahama Island.
"As a leader in cardiac cell therapy, Okyanos is very excited to bring this innovative treatment and new standard of care to patients in a near-shore, regulated jurisdiction, said Matt Feshbach, CEO and co-founder of Okyanos. Our innovative treatment will restore blood flow to the heart helping it begin the process of healing itself, thereby improving the quality of life for heart disease patients who have exhausted all other options.
Over 12 million Americans suffer from some form of heart disease costing $108.9 billion dollars annually in the US alone. Several million patients have now exhausted the currently available methods of treatment but continue to suffer daily from chronic heart disease symptoms such as shortness of breath, fatigue and chest discomfort that can make simple activities challenging. Cardiac cell therapy stimulates the growth of new blood vessels which can lead to reduced angina and reduced re-hospitalizations resulting in an improvement in quality of life.
The Okyanos procedure is performed by prestigious US-licensed chief cardiologist, Dr. Howard Walpole. It is the first cardiac cell therapy procedure for heart failure and disease available outside of clinical trials in which the bodys own adult stem cells, derived from fat tissue, are injected directly into the damaged part of the heart via a catheter to restore blood flow and repair tissue damaged by a heart attack or disease.
The procedure begins with the extraction of a small amount of your body fat, a process done using advanced water-assisted liposuction technology. After separating the fat tissue using a European Union-approved cell processing device the Okyanos cardiologist immediately injects these cells into and around the low blood flow regions of the heart via a cathetera protocol which allows for better targeting of the cells to repair damaged heart tissue. Because the treatment is minimally invasive it requires that patients be under only moderate sedation. Post-procedural recovery consists of rest in a private suite for several hours that comfortably accommodates up to 3 family members.
Okyanos Heart Institute is scheduled to begin delivery in the next several weeks. Patients can contact Okyanos at http://www.Okyanos.com or by calling toll free at 1-855-659-2667.
About Okyanos Heart Institute: (Oh key AH nos) Based in Freeport, Grand Bahama, Okyanos Heart Institutes mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by CEO Matt Feshbach and Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.A.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from ones own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive catheterization, stimulate the growth of new blood vessels, a process known as angiogenesis. Angiogenesis facilitates blood flow in the heart and supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos, the Greek god of the river Okeanos, symbolizes restoration of blood flow.
Read this article:
Okyanos Cardiac Cell Therapy Clinic Scheduled to Open
Stem Cell Therapy for Chronic Illness and So Called untreatable Diseases
Stem Cell Therapy with Mesenchymal stem cells are pluripotent and adult cells with fibroblastoid morphology and plasticity, toward various cell lineages such as chondrocytes, osteocytes and...
By: enjades
Read the rest here:
Stem Cell Therapy for Chronic Illness and So Called untreatable Diseases - Video
From the perspective of a community physician, the stem cell research, at this point, is not a priority. Given the daunting task of not only curing the present crop of diseases but also preventing them, and of course, building the human resource as the backbone of the health care system these should be the priority. Joseph Carabeo, convenor, Rx Abolish Pork Barrel Movement
By ANNE MARXZE D. UMIL Bulatlat.com
MANILA Eleazar Sobinsky, president of the Lung Center of the Philippines Employees Association-Alliance of Health Workers cannot decipher how the Disbursement Acceleration Program (DAP) has helped the poor. Of the P115 million ($263,822) DAP funds received by LCP, P70 million ($160,587) was spent for the stem cell research project and the rest was spent for the procurement of equipment.
He said if the DAP has helped the poor, why are there more indigent patients waiting in line at the LCPs out-patient department?
Joseph Carabeo, convenor of the Rx Abolish Pork Barrel Movement and a community doctor for the past 28 years, said that the stem cell research project does not even help solve the longtime health problems of Filipinos.
The stem cell research in LCP is a mispriority, said Carabeo in an interview with Bulatlat.com. There are many problems in the health sector that has to be addressed. We think, the DOH is merely riding the bandwagon on the stem cell research intervention in health care, wellness and primarily rejuvenation, Carabeo said.
Eleazar Sobinsky, union president of the Lung Center Employees Union said if the DAP has helped the poor, why are there more indigent patients waiting in line at the LCPs out-patient department? (Photo by A. Umil/ Bulatlat.com)
Stem cells according to http://www.stemcellnetwork.ca are the precursors of all cells in the human body.
Stem cells are very special, powerful cells found in both humans and non-human animals. They have been called the centerpiece of regenerative medicine medicine that involves growing new cells, tissues and organs to replace or repair those damaged by injury, disease or aging, the website said.
In the Philippines, Carabeo said, the medical community is not even united in the use of stem cell therapy in curing diseases. He said it is still under research in the Philippines. The Philippine Society of Endocrinology and Metabolism (PSEM) for one has even warned the public on the use of stem cell therapy as treatment for diabetes.
Go here to read the rest:
DAP-funded stem cell research a wrong priority
Stem Cell Therapy Testimonial
Arthritis Stem Cell Therapy Testimonial. Dr. Lox can be reached at http://www.drloxstemcells.com or Call (844) 440-8503 for information on Stem Cell Therapy.
By: Dr. Lox
See the original post here:
Stem Cell Therapy Testimonial - Video
This has reference to the article titled Regenerative medicinean alternative to facelifts and surgery by Alex Y. Vergara (Lifestyle Wellness section, 6/17/14).
The Food and Drug Administration (FDA) has noted that the procedureautologous platelet rich plasma (PRP) injections and cell therapy injections that involve cell extracts taken from sheep and rabbit fetuses featured in the article, i.e., getting the patients blood, processing it, and once the blood is processed, injecting its growth factors back to the patients anesthetized faceare analogous to stem cell procedure.
PRP and cell therapy injections are outside the initial three standard healthcare procedures recognized by the FDA, namely: hematopoietic stem cell transplantation, corneal resurfacing with limbal stem cells, and skin regeneration with epidermal stem cells.
The article also featured Swiss-made cellular products (known as MFIII Nano Cell Extracts and
Myopep Peptide Therapy) which are claimed to decrease fat buildup and to contour the body.
It must be stressed that the recognized skin regeneration procedure applies only to skin grafting for burn patients and not for any antiaging indications or aesthetic reason as featured in the subject news item.
To date, no human cells, tissues and cellular- and tissue-based products (HCT/Ps) are currently registered with the FDA; hence, any information on products and treatments which claims to use stem cells and the likewhether the information is in the form of an advertisement or information materialsis illegal as this could mislead the public on the standard of safety, efficacy and quality of the FDA-recognized HCT/P.
FDA highly recognizes the role of the media in promoting the consumers basic right to information. But it is our responsibility to give the consumers accurate facts and correct information to enable them to make an informed choice and be free from exploitation.
KENNETH Y.
HARTIGAN-GO, MD,
Read the original post:
FDA on alternative regenerative med
The treatment involves injecting up to 20 million stem cells into patients' brains. It was tested on patients at Glasgow's Southern General Hospital in 2012.
The Surrey-based company said it would work at 10 sites across the UK, including the Southern General, on a Phase II efficacy study of the ReN001 treatment involving 41 patients.
Loading article content
The treatment is designed to deliver a meaningful improvement in upper limb function in disabled stroke patients.
In May, the company said data from a long-term follow- up involving 11 patients included in a Phase I safety study of ReN001 at the Glasgow hospital observed sustained reductions in neurological impairment and spasticity in most patients. No cell-related or immunological adverse events were reported .
Yesterday, Reneuron said it has also started a Phase I safety study at Ninewells Hospital in Dundee of its ReN009 therapy for people with lower limb ischaemia. It will involve nine patients.
Reneuron says the disease is common in patients with diabetes and can lead to amputation of the limb.
See more here:
Reneuron tests stem cell stroke treatment
La Jolla, CA (PRWEB) September 03, 2014
A new study, published on Aug. 8th, 2014 in Stem Cells Translational Medicine, has shown the positive effect stem cell therapy has had on a group of patients only 6 months after their treatment. Researchers observed significant improvements in disease-related complications in each of the 5 patients included in the study. Post-treatment brain scans of each patient revealed that stroke-related damage was reduced over time. Further, at six-month follow-ups patients demonstrated improvements in standard measures of stroke-related disability and impairment.
Researchers are being cautiously optimistic when considering these results. Similar improvements are often seen in stroke patients as part of the normal recovery process and state that more thorough studies will need to be completed. Nonetheless, the findings are absolutely astounding as the five patients included in this study suffered severe strokes. Four out of five of the patients had the most serious type of stroke. Normally only 4% of these patients survive and are able to live independently after six months of a stroke occurrence.
Clinical studies for stem cell treatment are currently being offered by StemGenex to patients diagnosed with Stroke and other degenerative neurological diseases. Innovation is truly a driving force for StemGenex. Stroke Patients who receive stem cell treatment through StemGenex receive multiple therapeutic modalities they simply cannot find elsewhere under one roof, said Jeremiah McDole, Director of Scientific Research and Development at StemGenex. Offering targeted therapies that deliver stem cells past the blood brain barrier is essential to providing effective treatment for patients with neurological disorders.
StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Multiple Sclerosis, Parkinsons Alzheimers disease, and others. Rita Alexander, founder of StemGenex and the companys first stem cell patient, insists that all patients be treated like they are one of our loved ones. Hope, compassion, and the relentless pursuit for an end to these diseases are the primary focus.
To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact@stemgenex.com
Excerpt from:
Latest Study on Stem Cell Therapy Shows Promising Signs of Recovery for Stroke Patients and Support for StemGenex ...
ReNeuron Group Quote more
Price: 3.62
Chg: -0.19
Chg %: -4.87%
Date: 16:38
Stem cell therapy group Reneuron said it remains on track with the first patients having been dosed in two its clinical trials.
The phase II trial for the ReN001 cell therapy candidate for stroke disability and the phase I trail for ReN009 cell therapy candidate for critical limb ischaemia have both begun.
The ReN001 trial is on course to have generated six month follow-up data by the end of 2015, while ReN009 study should give results in the first half of next year.
Chief executive officer (CEO) Michael Hunt said that Reneuron's core therapeutic programmes remain on track towards "further important clinical milestones" over the next 18 months.
"In particular, the commencement of dosing of patients in two new clinical trials, in stroke and limb ischaemia, marks another significant step in Reneuron's evolution into a fully-fledged clinical development business and a leading player in the increasingly exciting field of cell therapy and regenerative medicine," Hunt said.
Read more:
Reneuron on track for clinical milestones as studies get underway
Stem Cell Activation Phuket, Thailand: How much does stem cell therapy cost
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/how-much-does-stem-cell-therapy-cost/ Find out about how much stem cell therapy will cost you...
By: Thanyapura Health Centre
See more here:
Stem Cell Activation Phuket, Thailand: How much does stem cell therapy cost - Video
Stem Cell Therapy as a Treatment Option for Osteoarthritis
Dr. Frank Garcia, board certified orthopedic surgeon with The San Antonio Orthopaedic Group, discusses the use of stem cell therapy in the treatment of osteo...
By: The San Antonio Orthopaedic Group
The rest is here:
Stem Cell Therapy as a Treatment Option for Osteoarthritis - Video
STEM CELL THERAPY: with DR ANDREW J. ROCHMAN
Dr. Andrew J Rochman is a leader in advanced surgical techniques, a native New Yorker and a Board-Certified Surgeon. His current undertaking involves promoting an educational advocacy in MODERN...
By: Modern Pain Relief
Read more from the original source:
STEM CELL THERAPY: with DR ANDREW J. ROCHMAN - Video
ABC Kellie van Meurs (3rd from R) died of a heart attack last month while receiving stem cell treatment in Moscow.
The death of an Australian woman undergoing stem cell therapy in Russia has prompted a leading stem cell research group to warn of rogue operators charging thousands of dollars for ineffectual treatments.
Brisbane mother Kellie van Meurs died of a heart attack last month while receiving stem cell treatment in Moscow for her rare neurological condition known as stiff person syndrome.
Stem Cells Australia said there was a growing number of patients going overseas for stem cell treatments which are limited in Australia.
A loophole in the therapeutic goods legislation means that doctors are legally allowed to treat patients, both here and overseas, with their own stem cells even if the treatment is unsafe or has not been proven effective through clinical trials.
Stem Cells Australia said it believed dozens of doctors in Australia offered the questionable treatments.
"They're selling treatment without any proof of benefit, and without any proof of safety," Associate Professor Megan Munsie, a stem cell biologist at the University of Melbourne, told the 7.30 program.
Annie Leverington was diagnosed with multiple sclerosis in 2007.
She was once a talented flamenco dancer and worked as a court stenographer.
But in 2002 she noticed something was wrong when her fingers started to "drop" during long trials.
More here:
Rogue stem cell therapy operators charging thousands for ineffective treatments, researchers say
LUMINESCE Stem cell Therapy Dr Nathan Newman
LUMINESCE Stem Cell Technology by JEUNESSE created from Telomere Research. Order Now: http://www.evenyounger.jeunesseglobal.com/PersonalCare.aspx?id=1.
By: Even Younger
See the original post:
LUMINESCE Stem cell Therapy Dr Nathan Newman - Video
Novartis ( NVS ) recently entered into an investment and option agreement with Israel-based Gamida Cell, a company which focuses on stem cell expansion technologies and therapeutic products.
As per the terms of the agreement, Novartis will invest $35 million in Gamida Cell. In exchange, Novartis will receive a 15% stake in Gamida Cell and an option to fully acquire the company.
The option for full acquisition is exercisable for a limited period of time following achievement of certain milestones in connection with the development of pipeline candidate, NiCord. These milestones are expected to be achieved during 2015. Novartis will also be required to pay the other shareholders in Gamida Cell approximately $165 million upon exercising the option along with potential milestone payments of $435 million.
We note that Gamida Cell is developing stem cell therapy for the potential treatment of blood cancers, solid tumors, non-malignant hematological diseases such as sickle cell disease and thalassemia, neutropenia and acute radiation syndrome, autoimmune diseases and genetic metabolic diseases as well as conditions that can be helped by regenerative medicine.
The company is currently evaluating NiCord for the potential treatment of hematological malignancies such as leukemia and lymphoma in a phase I/II study using its proprietary NAM technology.
Meanwhile, enrolment is on for the company's phase I/II study on NiCord for pediatric sickle cell disease.
We remind investors that Novartis has been taking strategic steps to realign its portfolio in order to focus on its core portfolio of pharmaceuticals, eye care and generics. Novartis' recent deal to acquire oncology products from GlaxoSmithKline ( GSK ) and the divestiture of the Vaccines business is a step in the right direction.
Novartis, a large-cap pharma, currently carries a Zacks Rank #3 (Hold). Right now, Allergan ( AGN ) and AbbVie ( ABBV ) look well positioned among the large-cap pharmas. While Allergan carries a Zacks Rank #1 (Strong Buy), AbbVie is a Zacks Rank #2 (Buy) stock.
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
Read the original here:
Novartis to Invest $35M in Gamida Cell for 15% Equity - Analyst Blog
(PRWEB UK) 21 August 2014
The success of stem cell medicine does not depend on funding alone
Funding is of the upmost importance but access to the right material is vital.
Stem Cell Banking of a childs own stem cells for potentially a lifetime of use, is a way of storing their health for their future. So it is vital that the right stem cells are available for treatment when they are needed at any time in their life.
Tony Veverka, Group CEO of specialist stem cell bank BioEden says, "Funding is of the upmost importance so that research can continue, but access to the right material is vital."
Gaining access to the right material for stem cell therapy has dramatically simplified since BioEden pioneered an entirely non-invasive method of taking stem cells from children's baby teeth. No longer is there just the option of stem cells from embryos, bone marrow or cord blood, but the option of taking quality cells from the baby tooth after it has fallen out naturally.
BioEden believes it can cut NHS funding dramatically by individuals banking their own stem cells, and they continue to call for clarity and transparency so that a prolonged and healthier life is accessible to all. http://www.thetimes.co.uk/tto/business/industries/health/article4181168.ece
Read this article:
The Times Have Published Only Half the Story, Says Specialist Stem Cell Bank BioEden